Navigating MS Treatment: The Role of Infusion Therapies
Navigating MS Treatment: The Role of Infusion Therapies
Understanding Infusions
Infusion therapies offer a potent approach to managing multiple sclerosis, but what should patients expect during treatment? Let's break it down.
Contents
- What Are Infusion Therapies?
- The Infusion Process
- Benefits and Considerations
What Are Infusion Therapies?
Infusion therapies involve administering medication directly into the bloodstream through an IV, allowing for precise dosing and rapid effects. For MS, these therapies include drugs like natalizumab and ocrelizumab, which target specific components of the immune system. They are often used in patients with active disease who need high-efficacy treatments.
The Infusion Process
Before starting an infusion, patients undergo screening for potential risk factors, such as infections. The infusion process typically involves premedication to prevent reactions, followed by the drug infusion under medical supervision. The procedure can take several hours, and patients are monitored for side effects during and after the infusion.
Benefits and Considerations
Infusion therapies can offer significant benefits, including reduced relapse rates and improved disease control. However, they require regular healthcare visits and carry risks such as infusion reactions and infections. Patients should discuss the pros and cons with their healthcare provider to determine the best approach for their MS management.
FAQs
What is an infusion therapy?
It's a method of delivering medication directly into the bloodstream.
Why are premedications used?
To prevent infusion reactions during the therapy.
How long does an infusion take?
The process can take several hours under medical supervision.
What are the main benefits?
They reduce relapse rates and improve disease control.
Next Steps
Infusion therapies are a powerful tool in MS treatment, providing significant benefits for many patients.
Additional References
- Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59:748.
- Patel A, Sul J, Gordon ML, et al. Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurol 2021; 78:736.
This article has been reviewed for accuracy by one of the licensed medical doctors working for Doctronic.